Johnson & Johnson $JNJ Stock Sold by Investment House LLC

Key Points

• Investment House LLC cut its Johnson & Johnson stake by 31.6% in the third quarter, selling 28,814 shares and retaining 62,371 shares valued at approximately $16.5 million. Institutional investors collectively own 69.55% of J&J.
• Wall Street remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $275.92. Recent targets range from $280 to $303.
• J&J reported quarterly EPS of $2.59, beating estimates, while revenue rose 5.9% year over year to $25.40 billion. The company also declared a $1.34 quarterly dividend, equivalent to a 2.0% annual yield.

Investment House LLC lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,371 shares of the company's stock after selling 28,814 shares during the quarter. Johnson & Johnson makes up 0.7% of Investment House LLC's investment portfolio, making the stock its 25th largest position. Investment House LLC's holdings in Johnson & Johnson were worth $16,512,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Silver Coast Investments LLC boosted its position in shares of Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV grew its stake in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after acquiring an additional 39 shares in the last quarter. Triumph Capital Management grew its stake in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Kwmg LLC lifted its stake in Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after purchasing an additional 39 shares in the last quarter. Finally, Cypress Wealth Services LLC lifted its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Cypress Wealth Services LLC now owns 10,618 shares of the company's stock worth $2,705,000 after purchasing an additional 39 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on JNJ shares. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research report on Thursday, October 15th. Evercore set a $300.00 price objective on Johnson & Johnson in a research note on Tuesday. Royal Bank Of Canada reduced their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a research report on Wednesday, October 14th. The Goldman Sachs Group restated a "buy" rating and issued a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Citigroup raised their price target on Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by corporate insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Johnson & Johnson Trading Down 1.3%

Shares of Johnson & Johnson stock opened at $264.13 on Friday. The company has a 50 day simple moving average of $265.64 and a two-hundred day simple moving average of $250.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81. The firm has a market cap of $635.85 billion, a PE ratio of 40.02, a PEG ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm posted $2.80 EPS. The firm's revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is 81.21%.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.